Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS). Pulmonary Vascular Disease (PVD) is a poorly understood but lethal condition. Currently, pulmonary hypertension (PH) is nosologically divided into Groups associated with primary vascular abnormalities, left-sided heart failure, pulmonary parenchymal and thromboembolic diseases. It is likely that these different forms of PH share common mechanistic pathways leading to PVD that might be targeted therapeutically, but currently these ostensible shared mechanisms remain poorly understood. In order to better understand the fundamental mechanisms of PVD in PH, this application seeks to enroll large numbers of people with each form of PH and perform detailed phenotyping of clinical, hemodynamic, functional, biomarker, metabolomic, and proteomic patterns.

Public Health Relevance

Pulmonary hypertension (PH) is a poorly understood and deadly condition that can be caused by numerous processes. Treatment options for the majority of patients with PH are limited, and in this research, we seek to rigorously characterize different forms of PH to help develop new treatment strategies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL125205-02
Application #
8927055
Study Section
Special Emphasis Panel (ZHL1-CSR-P (S1))
Program Officer
Xiao, Lei
Project Start
2014-09-15
Project End
2019-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
2
Fiscal Year
2015
Total Cost
$314,738
Indirect Cost
$85,481
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Obokata, Masaru; Borlaug, Barry A (2018) Stress Imaging in Heart Failure: Physiologic, Diagnostic, and Therapeutic Insights. Circ Cardiovasc Imaging 11:e007785
Reddy, Yogesh N V; Carter, Rickey E; Obokata, Masaru et al. (2018) A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation 138:861-870
Reddy, Yogesh N V; Olson, Thomas P; Obokata, Masaru et al. (2018) Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 6:665-675
Obokata, Masaru; Borlaug, Barry A (2018) The strengths and limitations of E/e' in heart failure with preserved ejection fraction. Eur J Heart Fail 20:1312-1314
Fayyaz, Ahmed U; Edwards, William D; Maleszewski, Joseph J et al. (2018) Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation 137:1796-1810
Borlaug, Barry A (2018) Can Oxygen Transport Analysis Tell Us Why People With Heart Failure With Preserved Ejection Fraction Feel So Poorly? Circulation 137:162-165
Hemnes, Anna R; Beck, Gerald J; Newman, John H et al. (2017) PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics. Circ Res 121:1136-1139
Frantz, Robert P (2015) Whither Anticoagulation in Pulmonary Arterial Hypertension? Conflicting Evidence REVEALed. Circulation 132:2360-2